Genelux Corporation Prices Public Offering of 6,666,667 Shares at $3.00 Each
Genelux Corporation announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20M, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. In addition, Genelux has granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares of its common stock at the price to the public, less underwriting discounts and commissions. The net proceeds from the offering are expected to be used for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. The offering is expected to close on or about January 9, 2026, subject to the satisfaction of customary closing conditions. Lucid Capital Markets is acting as the sole book-running manager for the proposed offering.
